olaparib,bevacizumab
roche,astrazeneca,merck
['paola1', 'olaparib', 'ovarian']
#esmo2022 paola1 trial: 65.5% of patients with hrd+ ovarian cancer treated with olaparib+bev alive at 5 years vs 48.4% in bev. increasing survival in aoc. participation of 
Spanish Ovarian Cancer Research Group (GEICO). Grupo Español de Investigación en Cáncer de Ovario y Tumores Ginecológicos. #cancerginecológico #GynCancer